Tenax Therapeutics (NasdaqCM:TENX) 2026 Conference Transcript

Tenax Therapeutics Conference Call Summary Company Overview - Company: Tenax Therapeutics (NasdaqCM:TENX) - Event: 2026 Conference on March 10, 2026 - Speakers: Christopher Giordano (CEO), Stuart Rich (Chief Medical Officer) Key Points Industry and Product Focus - Industry: Pharmaceutical, specifically focusing on treatments for pulmonary hypertension and heart failure - Product: Oral levosimendan, aimed at treating patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) [1][2] Enrollment and Study Updates - LEVEL Study Enrollment: Achieved target of 230 PH-HFpEF patients randomized, completed ahead of schedule in approximately 2 years [2] - Study Timeline: Randomization expected to conclude in March, with results anticipated in the third quarter of 2026 [2] - Patient Retention: High retention rate in the trial, with over 90% of patients entering the open-label extension (OLE) phase [16][17] Financial Health - Liquidity: Improved liquidity since PIPE financing, with sufficient cash to fund operations for approximately 18 months beyond data readout [3] Mechanism of Action - Mechanism: Oral levosimendan works by redistributing blood volume from splanchnic circulation to the lungs, addressing the issue of pulmonary hypertension in PH-HFpEF patients [11][12] - Clinical Evidence: Previous trials (HELP) demonstrated that levosimendan effectively reduces right atrial pressure and pulmonary artery pressure while maintaining cardiac output [13][14] Patient Experience and Anecdotal Evidence - Patient Feedback: Patients report significant improvements in quality of life, with anecdotes of increased activity levels and ability to perform daily tasks [53] - Placebo Effect Considerations: Patient responses can vary based on their initial health status; sicker patients are less likely to improve on placebo [19] Statistical Analysis and Trial Design - Sample Size Reassessment: Adjusted sample size based on interim analysis, increasing the power of the study to over 90% [30][35] - Expected Outcomes: Targeting a 25-meter improvement in the six-minute walk test, which is considered clinically meaningful for this patient population [37] Global Expansion Plans - Future Trials: Plans for LEVEL Two trial with a larger footprint, aiming to recruit in multiple countries including the U.S., Europe, Korea, and Taiwan [57][58] - Recruitment Strategy: Leveraging existing relationships with pulmonary hypertension experts to enhance recruitment efforts [59] Regulatory Considerations - FDA Interactions: Ongoing discussions with regulatory experts regarding potential pathways for drug approval, including the possibility of rolling submissions based on safety data [69][70] Company Growth and Structure - Workforce Expansion: Tripled employee count since raising funds, focusing on building relationships with investigators and opinion leaders globally [73][75] - Commercialization Strategy: Preparing for global commercialization with a focus on pre-commercial relationship management and medical teams [75] Additional Insights - Market Potential: Approximately 80% of HFpEF patients may have pulmonary hypertension, indicating a significant market opportunity for oral levosimendan if approved [23][24] - Patient Demographics: LEVEL trial participants are less symptomatic compared to those in the HELP trial, which may influence treatment outcomes [22] This summary encapsulates the critical insights from the Tenax Therapeutics conference call, highlighting the company's advancements, study progress, and strategic plans within the pharmaceutical industry.